The Top 5 Biosimilars Articles for the Week of August 28

The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 28, 2017.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 28.

Number 5: A recent study concluded that reference pricing can help drive down the cost of drugs for health plans, but can raise out-of-pocket costs for patients.

Number 4: Amgen and Sandoz have filed new briefs stating their positions on how the lower courts should address their claims after the Supreme Court’s recent ruling in Sandoz v Amgen.

Number 3: Ireland’s National Cancer Control Programme has issued new guidance on the use of biosimilar medicines in the treatment of cancer.

Number 2: Drug maker Biocon has announced that the FDA will delay a decision on its trastuzumab biosimilar by 3 months.

And Number 1: The FDA has approved Boehringer Ingelheim’s adalimumab biosimilar. Cyltezo is the second FDA-approved biosimilar of the blockbuster reference drug, Humira.

Finally, last week, our newsletter asked you to share your thoughts about whether drug pricing contracts between reference product developers and payers are bad news for biosimilars. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.